Wellend Health

Our research

Our unique suite of Intellectual Property has been developed over 30 years of focused preclinical, translational and clinical research. Through our sister company Havah, an Australia-based biotechnology company specialising in the development of hormonal therapeutics targeting breast health, we have developed hormonal therapeutics for both breast cancer prevention and improving breast cancer treatment.

In conjunction with Chavah, we collaborate with world leaders and medical science pioneers to develop a cutting-edge treatment platform for our patients through partnership with GTx, Inc. (NASDAQ:GTXI), Supersonic Imagine SA (EPA:SSI) and Volpara Solutions Ltd (ASX: VHT). We are involved in National Cancer Institute (U.S.) backed multicentre clinical trials of our IP across the U.S. in partnership with the world-renowned Mayo Clinic.

Our research and development projects have benefited from significant funding and support from both the public and private sector including global pharmaceutical giant AstraZeneca Plc.

Over 30 years of focused preclinical, translational and clinical research.

Clinical trails

Wellend is currently involved in a number of Phase II clinical trials in the fields of breast cancer prevention and breast cancer treatment in partnership with sister company Chavah and partner GTx.

Our current clinical studies focus on the utilisation of Selective Androgen Receptor Modulators in the management of breast health.‚Äč

Participation

Participation in clinical studies helps bridge the gap between ground-breaking research and achieving improved patient outcomes and care.

Please contact us if you are interested in participating in any of our clinical trials.

CONTACT US

Clinical Trial News

Current Clinical Trials

  • Chavah SARM+Ai mammographic breast density reduction
    PHASE II

    A Phase II single-centre study investigating the efficacy and safety of GTx-024 and anastrozole in peri-menopausal women with high mammographic breast density.

  • GTx Enobosarm trial 1
    PHASE II

    A Phase II open label, multi-center, multinational, randomized, parallel design study investigating the efficacy and safety of GTx-024 on metastatic or locally advanced ER+/AR+ breast cancer in postmenopausal women.

  • GTx Enobosarm trial 2
    PHASE II

    A Phase II open label, multi-center, multinational study investigating the efficacy and safety of GTx-024 on advanced, androgen receptor-positive triple negative breast cancer (AR+ TNBC).

  • For information on our current clinical trials to learn more about our research, development and Intellectual Property please contact Nicholas Birrell, Managing Director.

Subscribe to our blog and stay informed